(Albany, United States) As per DelveInsight’s assessment, globally, the Gastric Cancer Pipeline constitutes 230+ key companies continuously working towards developing 230+ Gastric Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Gastric Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Gastric Cancer NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Gastric Cancer Pipeline treatment landscape of the report, click here @ Gastric Cancer Pipeline Outlook

 

Key Takeaways from the Gastric Cancer Pipeline Report

• DelveInsight’s Gastric Cancer Pipeline analysis depicts a robust space with 230+ active players working to develop 230+ pipeline treatment therapies.
• The leading companies working in the Gastric Cancer Market include Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology Inc., Merck KGaA, Shanghai Henlius Biotech, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, Merck Sharp & Dohme LLC, AB Science, Maxinovel, Shanghai Miracogen Inc, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Bayer, Hutchison Medipharma Limited, and others.
• Promising Gastric Cancer Pipeline Therapies in the various stages of development include S-1/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.
• On June 2023, Bristol-Myers Squibb announced a study of phase 2 clinical trials for Nivolumab, Ipilimumab, Relatlimab, BMS-986205 and Rucaparib. The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
• On July 2023, Ono Pharmaceuticals Co. Ltd announced a study of phase 3 clinical trials for Nivolumab, Oxaliplatin, and Capecitabine. The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

 

Gastric Cancer Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over.

 

For further information, refer to the detailed Gastric Cancer Unmet Needs, click here for Gastric Cancer Ongoing Clinical Trial Analysis

 

Gastric Cancer Emerging Drugs Profile

• BI308: Innovent Biologics
• HLX10: Henlix Biotech
• Pamiparib: BeiGene

 

Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 230+ key companies that are developing therapies for Gastric Cancer. The Gastric Cancer companies that have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include Innovent Biologics.

 

Request a sample and discover the recent advances in Gastric Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Gastric Cancer Segmentation

 

Gastric Cancer Drugs and Companies

• S-1/Cisplatin: Taiho Oncology Inc.
• 5-FU/cisplatin: Quintiles Inc.
• FLX475: Hanmi Pharmaceuticals Co. Ltd
• Pembrolizumab: Merck Sharp & Dohme LLC

 

Gastric Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Gastric Cancer Therapeutics Market include-

Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology Inc., Merck KGaA, Shanghai Henlius Biotech, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, Merck Sharp & Dohme LLC, AB Science, Maxinovel, Shanghai Miracogen Inc, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Bayer, Hutchison Medipharma Limited, and others.

 

Dive deep into rich insights for drugs for the Gastric Cancer Pipeline, Click here @ Gastric Cancer Unmet Needs and Analyst Views

 

Scope of the Gastric Cancer Pipeline Report

• Coverage- Global
• Companies- Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology Inc., Merck KGaA, Shanghai Henlius Biotech, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, Merck Sharp & Dohme LLC, AB Science, Maxinovel, Shanghai Miracogen Inc, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Bayer, Hutchison Medipharma Limited, and others.
• Therapies- S-1/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Gastric Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. IBI308: Innovent Biologics
8. Drug profiles in the detailed report…..
9. Mid-Stage Products (Phase II)
10. Pamiparib: BeiGene
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. HC 5404 FU: HiberCell
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. PolyPEPI 1311: Treos Bio
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Gastric Cancer Key Companies
20. Gastric Cancer Key Products
21. Gastric Cancer- Unmet Needs
22. Gastric Cancer- Market Drivers and Barriers
23. Gastric Cancer- Future Perspectives and Conclusion
24. Gastric Cancer Analyst Views
25. Gastric Cancer Key Companies
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services